RPbio Inc.

RPbio Inc.

KKRX:314140
4,990.00
KRW
-110.00
(-2.16%)
777.91EPS
6.80P/E
45.76BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
10,657.28
14,893.63
17,489.32
19,745.22
17,501.35
14,349.19
15,739.05
16,357.36
Basic EPS, GAAP
437
702
580
617
630
-105
541
777.91
Free Cash Flow per Basic Share
-4,553.8
-798.35
332.95
-589.62
-67.7
869.59
793.14
891.86
Dividend per Share
- -
- -
- -
- -
- -
50.06
- -
- -
Book Value per Share
7,178.4
7,817.6
8,316.06
11,145.28
11,878.43
11,827.16
12,393.03
13,497.24
Tangible Book Value per Share
7,092.91
7,724.19
8,247.09
11,089.77
11,839.68
11,769.88
12,305.58
13,429.7
Basic Weighted Avg Shares
7
7
7
7
9
9
9
9
Sales/Revenue/Turnover
69,855
97,923
114,964
138,109
151,046
123,967
136,219
141,425
Operating Margin (%)
3.97
4.25
5.11
6.98
4.38
-0.56
3.73
5.28
Depreciation Expense
2,796
4,414
5,203
5,403
6,048
6,818
6,412
6,079
Net Income, GAAP
2,864
4,616
3,813
4,316
5,437
-907
4,682
6,726
Effective Tax Rate (%)
- -
- -
11.15
23.87
3.9
- -
- -
6.88
Profit Margin (%)
4.1
4.71
3.32
3.12
3.6
-0.73
3.44
4.76
Working Capital
-6,951
-25,109
-23,179
2,413
10,218
9,937
13,177
20,594
LT Debt
17,848
384
2,858
2,635
4,774
4,593
3,139
3,007
Total Equity
56,045
61,035
64,927
91,137
102,747
102,303
107,198
116,749
Return on Invested Capital (%)
- -
- -
5.06
6.24
4.83
- -
- -
5.26
Return on Capital (%)
- -
- -
4.54
4.45
5.45
- -
- -
5.56
Return on Common Equity (%)
- -
7.88
6.05
5.53
5.61
-0.88
4.47
6.07

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16,309
16,257
16,236
LT Borrowings
- -
- -
- -
LT Finance Leases
3,139
3,067
3,007
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
64,009
54,235
45,758

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
57,581
66,883
70,101
Cash, Cash Equivalents & STI
14,626
23,037
19,763
Accounts Receivable, Net
18,499
17,019
19,750
Inventories
24,137
26,271
29,123
Total Current Liabilities
44,404
50,039
49,507
Payables & Accruals
- -
- -
- -
ST Debt
16,309
16,257
16,236
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.77%
4.78%
Free Cash Flow
- -
-382.06%
-8.63%
Net Income, GAAP
- -
-142.21%
-616.17%
Sales/Revenue/Turnover
- -
7.77%
9.88%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
32,488
32,079
28,100
31,299
123,967
2025
33,992
35,699
33,216
33,312
136,219
2026
35,127
39,770
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-60
14
-182
123.64
-105
2025
196
214
31.94
99.75
541
2026
302.49
344
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
50.06
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Full Time Employees
534
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Seoul South Korea
IPO Date
Sep 29, 2022
Business
RPbio Inc. is a South Korea-based pharmaceutical and nutritional healthcare company that specializes in the research, development, contract development and manufacturing (CDMO), original equipment manufacturing (OEM), and original design manufacturing (ODM) of soft gelatin capsules, health functional foods, and specialty oral dosage forms. Founded in 1983 as RP Scherer Korea, a joint venture between Daewoong Pharmaceutical Co., Ltd. and R.P. Scherer Corporation, the company is headquartered in Seoul, South Korea, and operates advanced production and research facilities in Hyangnam and Mado, Gyeonggi Province. RPbio Inc. is listed on the Korea Exchange under the ticker symbol KRX:314140 and serves domestic and international pharmaceutical firms, healthcare enterprises, and consumer health brand owners, including Daewoong Pharmaceutical, Chong Kun Dang, and Yuhan Corporation. The company's core operations are structured into two principal business divisions: Pharmaceuticals and Health Functional Foods. RPbio Inc. manufactures and supplies a comprehensive portfolio of products and formulation technologies, including: over-the-counter (OTC) and prescription pharmaceuticals, comprising cold and flu remedies, antipyretic analgesics, nonsteroidal anti-inflammatory drugs, hepatoprotective and liver support agents, cardiovascular and circulatory regulators, and therapeutic vitamin compounds; health functional food supplements, comprising omega-3 fish oil, lutein and zeaxanthin eye health formulations, coenzyme Q10, customized multivitamin complexes, minerals, and dietary health nutrients; specialized oral delivery dosage forms, comprising traditional soft gelatin capsules, plant-based vegetarian soft capsules, enteric-coated soft capsules, chewable capsules, and dual-formulation liquid-gel complexes; and proprietary formulation platforms, comprising Neosol and New Neosol solubility enhancement technology for improving the bioavailability and dissolution rates of hydrophobic active pharmaceutical ingredients, Neogel and New Neogel shell stability technology designed to prevent capsule leakage, hardening, and degradation over extended shelf lives, and sustained-release encapsulation systems. In recent operational developments, RPbio Inc. has accelerated its global CDMO expansion and diversified its formulation portfolio. The company developed and commercialized Blister Jelly and Boost Jelly, an innovative oral dosage format utilizing automated direct-fill aluminum-aluminum (Alu-Alu) blister packaging technology to prevent oxidation, maintain active ingredient integrity, and address consumer demand for functional confectionery-style supplements. To support rising domestic and international order volumes, the company completed a substantial manufacturing capacity expansion at its Mado facility, increasing production output by more than 70 percent. Internationally, RPbio Inc. successfully completed a United States Food and Drug Administration (FDA) current Good Manufacturing Practice (cGMP) site inspection with Voluntary Action Indicated (VAI) status, secured international FSSC 22000 food safety system certification, and obtained United Kingdom FAPAS proficiency verification to advance direct contract manufacturing exports across North America and the Asia-Pacific region. Strategically, the company launched an enterprise-wide digital transformation (DX) initiative to implement smart manufacturing systems and completed executive leadership realignments under Chief Executive Officer Yoon Jae-hoon to reinforce corporate governance and commercial execution.